Since its inception in 1939, the U-M Department of Radiation Oncology has built and maintained its distinguished position as a national leader in providing first-rate cancer care and producing cutting-edge research to advance the effectiveness and success of cancer treatment. Today, under the leadership of director Dr. Theodore Lawrence, Isadore Lampe Professor and Chair, the Department enjoys a well-earned reputation as an authority in treating:

Why is the University of Michigan Department of Radiation Oncology your best resource for cancer care?

A Reputation for Innovation

We are committed to offering patients the latest advances in treatment. Our pioneering research efforts include the invention of three-dimensional treatment planning, now a standard practice worldwide. We have continued this research by developing a unique method of delivering intensity modulated radiation therapy (IMRT). In addition to these technical developments, our scientists are designing better ways of combining medications with radiation so as to more effectively treat tumors, spare normal tissue from damage, and minimize side effects. Radiation Oncology at Michigan receives more research funding from the National Institutes of Health than any radiation oncology department in the nation.

• The University of Michigan Hospitals and Health Centers is listed among the best hospitals in the nation and once again is the only hospital in Michigan to make the honor roll of “America’s Best Hospitals” in the annual U.S.News & World Report rankings.
• By working collaboratively with the U-M's renowned Comprehensive Cancer Center as well as our statewide Radiation Oncology Network, we provide accessible, appropriate patient care throughout Michigan and across multiple disciplines. We bring fundamental discoveries in cancer biology and medical physics directly to the clinic to help patients.
  
• The Department has developed breakthrough radiotherapy and expertise in combining radiation with chemotherapy to deliver a new generation of molecularly targeted treatments.
  
• We produce competent clinical and scientific leaders with a training program that integrates biology laboratory, medical physics, clinic experience and symptom management.
  
• External beam radiation, including intensity-modulated radiation therapy (IMRT)
• Prostate seed implants
• Stereotactic radiosurgery and radiotherapy for lesions anywhere in the body.
• High dose-rate (HDR) and low dose-rate (LDR) brachytherapy
• Our faculty are actively involved in developing the latest clinical trials, departmentally and through cooperative group studies (Radiation Therapy Oncology Group, Southwest Oncology Group, Children’s Cancer Study Group and others).
• State-of-the-art telemedicine and videoconferencing make it possible to evaluate a patient at one partner site and perform radiation treatment planning at a different site. Every case within the Radiation Oncology Network is reviewed by U-M faculty physicians assuring the highest level of care.